ISIN IE00BYZK4776TER 0.40%Assets 1,311 M €
Volatility 1y 16%Worst fall 1y −12%Since 2016-09-08
Themes · general research
Genomics and biotech platforms
Sequencing, DNA synthesis, gene editing, AI drug discovery and diagnostics.
Can lose most
Can lose most of the money. Typical volatility 73%, typical worst fall −85%; 3 of 7 companies are more than half below their high.
The weakest basket of the last four years (+1 %). Gene-editing names are 50–92 % below their highs, with binary clinical risk.
Typical volatilityMedian 1-year volatility of the theme's companies (annualised daily moves).
73%
Typical worst fallMedian of each company's worst peak-to-trough fall in five years (or since listing).
−85%
Typical distance from the high
−50%
Typical 1-year return
−26%
How to hold it in the EU
US-listed ETFs have no KID and cannot be bought by EU retail investors; these UCITS lines can. One fund line spreads the single-company risk.
ISIN IE00BYXG2H39TER 0.35%Assets 1,016 M €
Volatility 1y 22%Worst fall 1y −7%Since 2017-10-19
Green: available; dashed with “?”: the venue is offered, check the line in the terminal; crossed out: not available.
US theme ETFs (ARKG) are used only to measure the theme's risk: not buyable by EU retail.
The companies
Research data of 2026-10-15; where we score the company, its live Smart Score and red flags are shown.
| Ticker | Market cap | Revenue (y/y) | P/S | Volatility 1y | Worst fall | From high | 1 year | 12 m: ×2 / −50 % | Where | Our rating |
|---|---|---|---|---|---|---|---|---|---|---|
| ILMN Illumina: DNA sequencing | 41.0 B$ | 4.5 B$ (+5%) | 9× | 48% | −83% | −35% | +186% | 5% / 3% | Freedom24IBKR | 8/10 |
| TEM Tempus AI: AI diagnostics | 12.3 B$ | 1.4 B$ (+50%) | 9× | 73% | −60% | −34% | −28% | 4% / 0% | Freedom24IBKR | 1/10Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary →Caution. Negative free cash flow in at least two of the last three years. More in the glossary →+1 |
| CRSP CRISPR Therapeutics: gene editing (Casgevy) | 4.9 B$ | 13 M$ (−65%) | 363× | 58% | −69% | −50% | −26% | 0% / 1% | Freedom24IBKR | 1/10Caution. Negative free cash flow in at least two of the last three years. More in the glossary →Caution. Share count growing 3–10 % a year over three years. More in the glossary → |
| TWST Twist: DNA synthesis | 9.3 B$ | 432 M$ (+19%) | 22× | 78% | −92% | −28% | +392% | 27% / 18% | Freedom24IBKR | 1/10Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary →Caution. Negative free cash flow in at least two of the last three years. More in the glossary →+1 |
| BEAM Beam: base editing | 2.4 B$ | 156 M$ (+159%) | 15× | 72% | −85% | −76% | −7% | 1% / 10% | Freedom24IBKR | 1/10Serious warning. Share count growing more than 10 % a year over three years. More in the glossary →Caution. Negative free cash flow in at least two of the last three years. More in the glossary →+1 |
| NTLA Intellia: in-vivo gene editing | 1.6 B$ | 60 M$ (+13%) | 27× | 98% | −95% | −92% | −52% | 1% / 29% | Freedom24IBKR | 1/10Serious warning. Share count growing more than 10 % a year over three years. More in the glossary →Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary →+1 |
| RXRX Recursion: AI drug discovery | 2.0 B$ | 55 M$ (−15%) | 37× | 74% | −86% | −82% | −32% | 0% / 9% | Freedom24IBKR | 1/10Serious warning. Share count growing more than 10 % a year over three years. More in the glossary →Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary →+1 |
Survivorship: the list is of companies known in 2026; earlier names that went bankrupt or were taken private are missing, so the “×2” share is an upper bound.
The theme as a basket
Equal weights, monthly rebalance, 08.08.2022–14.10.2026, compared with the S&P 500.
| Equal-weight basket | CAGR | Volatility 1y | Worst fall | 1 year |
|---|---|---|---|---|
| CRSP NTLA BEAM RXRX TWST ILMN | 0% | 53% | −59% | +31% |
| S&P 500 (SPY) | +15% | 16% | −19% | +13% |
The window starts near the 2022 low, which flatters every basket. Past results do not predict future ones.
Base rates: how such bets usually end
Research results to keep in mind before any upside.
IPOs, 3 years38.5% of IPOs lost more than half in 3 years; 16.1% doubled, 0.5% grew 11× or more.
Jay Ritter, IPO statistics, Table 16e (9,195 IPOs 1975–2021), 23.03.2026
SPAC mergers−51% average 1-year return after a SPAC merger (2012–2024).
Ritter / Gahng–Ritter–Zhang, Table 15c (625 de-SPACs 2012–2024), 05.10.2026
Thematic ETFs−30% risk-adjusted over the first 5 years of specialised (thematic) ETFs.
Lottery stocks> 1% a month: how much “lottery” stocks (the biggest one-day jumps) underperform.
Where the gains come from4% of US stocks created all the net wealth since 1926.
Volatility drag≈ 46% a year is lost to volatility at 96% volatility: +40 % a year on average compounds to about −6 %.
standard approximation: geometric mean ≈ arithmetic mean − σ²/2 (our arithmetic)
Quantum computingAI infrastructure and chipsNuclear power and small reactorsSpaceRobotics and autonomyCrypto equities and bitcoin products
Source: Nasdaq historical closes 15.10.2021–14.10.2026; stockanalysis.com fundamentals 15.10.2026; justETF profiles and quotes 15.10.2026 · Research data of 2026-10-15 · Methodology and sources
Bertarik daripada kontrak di sini · Pengguna EU: 14 hari untuk menarik diri daripada pembelian.